Thursday, 30 July 2020

Remdesivir maker Gilead Sciences sees 10% drop in second-quarter sales as demand for non-coronavirus drugs falls

Gilead Sciences' sales fell 10% in the second quarter from a year earlier as the coronavirus pandemic weakened demand for some of its drugs, including some of its core hepatitis treatments.

from Earnings https://ift.tt/3jZZ794
via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)